Business Description
Avacta Group PLC
ISIN : GB00BYYW9G87
Description
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.16 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 0.98 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.15 | |||||
| Beneish M-Score | -3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.3 | |||||
| 3-Year EBITDA Growth Rate | -7 | |||||
| 3-Year EPS without NRI Growth Rate | 4.7 | |||||
| 3-Year FCF Growth Rate | 18.1 | |||||
| 3-Year Book Growth Rate | -39.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 0.03 | |||||
| 14-Day RSI | 0.64 | |||||
| 6-1 Month Momentum % | -66.83 | |||||
| 12-1 Month Momentum % | -47.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.71 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.45 | |||||
| Days Inventory | 82.02 | |||||
| Days Sales Outstanding | 120.92 | |||||
| Days Payable | 298.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -56.8 | |||||
| Shareholder Yield % | -18.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.4 | |||||
| Operating Margin % | -187.17 | |||||
| Net Margin % | -267 | |||||
| FCF Margin % | -96.68 | |||||
| ROE % | -166.35 | |||||
| ROA % | -56.83 | |||||
| ROIC % | -38.73 | |||||
| ROC (Joel Greenblatt) % | -356.75 | |||||
| ROCE % | -110.42 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.42 | |||||
| PB Ratio | 5.49 | |||||
| EV-to-EBIT | -4.42 | |||||
| EV-to-EBITDA | -4.9 | |||||
| EV-to-Forward-EBITDA | -5.68 | |||||
| EV-to-Revenue | 9.72 | |||||
| EV-to-Forward-Revenue | 6.85 | |||||
| EV-to-FCF | -9.98 | |||||
| Price-to-Median-PS-Value | 0.53 | |||||
| Earnings Yield (Greenblatt) % | -22.62 | |||||
| FCF Yield % | -9.79 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers